# Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.

> **NCT03508167** · PHASE3 · WITHDRAWN · sponsor: **Ache Laboratorios Farmaceuticos S.A.**

## Conditions studied

- Low Back Pain

## Interventions

- **DEVICE:** Thermal Band
- **DRUG:** Dorilax®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03508167
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01
- **Primary completion:** 2020-10
- **Final completion:** 2020-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study design will be reformulated
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508167, "Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03508167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*